CD274 and non-small cell lung carcinoma: Among patients with NSCLC with high PD‐L1 expression, combination immunotherapy should be selected for those with a good C‐PLAN index, considering that approximately 30% of patients with NSCLC who receive ICI monotherapy develop PD within 3 months.